Intravitreal Injections of Ranibizumab With Deferred Laser Grid Laser Photocoagulation for Treatment of Diabetic Macular Edema With Visual Impairment

Sponsor
Poitiers University Hospital
Study ID
NCT01823965
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 79 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

In the prospective monocentric open label trial patients with diabetic macular edema will be treated with intravitreal injections of ranibizumab given for 3 months then with laser grid at month 4. During follow-up a ranibizumab injection will be performed every 2 months in case of best-corrected visual acuity decreased more than 5 letters.

Key Dates

First listed
Apr 4, 2013
Start date
Oct 31, 2011
Status verified
Mar 2016
Primary completion
Jul 31, 2014
Completion
Jul 31, 2014

Study Design

Enrollment
35 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: ranibizumab

Primary Outcome Measure

Number of intravitreal injections of ranibizumab [ Time Frame: 1 years ]

Related Studies